SRRK vs. BCRX, CGEM, AUTL, IMTX, PROK, FDMT, VIR, RLAY, MESO, and TARS
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include BioCryst Pharmaceuticals (BCRX), Cullinan Oncology (CGEM), Autolus Therapeutics (AUTL), Immatics (IMTX), ProKidney (PROK), 4D Molecular Therapeutics (FDMT), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Mesoblast (MESO), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Scholar Rock (NASDAQ:SRRK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Scholar Rock has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -58.69%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Scholar Rock's return on equity.
Scholar Rock currently has a consensus price target of $25.17, indicating a potential upside of 101.49%. BioCryst Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 122.93%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Scholar Rock.
In the previous week, BioCryst Pharmaceuticals had 5 more articles in the media than Scholar Rock. MarketBeat recorded 16 mentions for BioCryst Pharmaceuticals and 11 mentions for Scholar Rock. BioCryst Pharmaceuticals' average media sentiment score of 1.11 beat Scholar Rock's score of 0.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
Scholar Rock has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 26.2% of Scholar Rock shares are held by insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioCryst Pharmaceuticals received 329 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 66.43% of users gave BioCryst Pharmaceuticals an outperform vote while only 63.25% of users gave Scholar Rock an outperform vote.
Scholar Rock has higher earnings, but lower revenue than BioCryst Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
BioCryst Pharmaceuticals beats Scholar Rock on 12 of the 19 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
